Annual SG&A
$77.42 M
-$14.92 M-16.15%
31 December 2023
Summary:
Nektar Therapeutics annual selling, general & administrative expenses is currently $77.42 million, with the most recent change of -$14.92 million (-16.15%) on 31 December 2023. During the last 3 years, it has fallen by -$27.27 million (-26.05%). NKTR annual SG&A is now -36.98% below its all-time high of $122.84 million, reached on 31 December 2021.NKTR Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$18.96 M
-$1.55 M-7.57%
30 September 2024
Summary:
Nektar Therapeutics quarterly selling, general & administrative expenses is currently $18.96 million, with the most recent change of -$1.55 million (-7.57%) on 30 September 2024. Over the past year, it has dropped by -$2.19 million (-10.36%). NKTR quarterly SG&A is now -41.02% below its all-time high of $32.14 million, reached on 31 December 2021.NKTR Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$14.16 B
-$168.30 M-1.20%
30 September 2024
Summary:
Nektar Therapeutics TTM selling, general & administrative expenses is currently -$14.16 billion, with the most recent change of -$168.30 million (-1.20%) on 30 September 2024. Over the past year, it has dropped by -$14.24 billion (-17362.16%). NKTR TTM SG&A is now -235919.75% below its all-time high of $122.84 million, reached on 31 December 2021.NKTR TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NKTR Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -16.1% | -10.4% | -10000.0% |
| 3 y3 years | -26.1% | -35.7% | -10000.0% |
| 5 y5 years | -4.9% | -21.0% | -10000.0% |
NKTR Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -37.0% | at low | -41.0% | +9.4% | -41.8% | at low |
| 5 y | 5 years | -37.0% | at low | -41.0% | +9.4% | -122.3% | at low |
| alltime | all time | -37.0% | +2319.3% | -41.0% | +4639.3% | <-9999.0% | at low |
Nektar Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $18.96 M(-7.6%) | $76.94 M(-2.8%) |
| June 2024 | - | $20.51 M(+1.8%) | $79.13 M(+3.5%) |
| Mar 2024 | - | $20.15 M(+16.3%) | $76.48 M(-1.2%) |
| Dec 2023 | $77.42 M(-16.2%) | $17.32 M(-18.1%) | $77.42 M(-5.6%) |
| Sept 2023 | - | $21.15 M(+18.3%) | $82.04 M(-1.7%) |
| June 2023 | - | $17.87 M(-15.2%) | $83.42 M(-3.1%) |
| Mar 2023 | - | $21.08 M(-3.9%) | $86.08 M(-6.8%) |
| Dec 2022 | $92.33 M(-24.8%) | $21.94 M(-2.6%) | $92.33 M(-10.0%) |
| Sept 2022 | - | $22.53 M(+9.8%) | $102.54 M(-6.3%) |
| June 2022 | - | $20.52 M(-24.9%) | $109.47 M(-7.6%) |
| Mar 2022 | - | $27.34 M(-14.9%) | $118.50 M(-3.5%) |
| Dec 2021 | $122.84 M(+17.3%) | $32.14 M(+9.1%) | $122.84 M(+4.2%) |
| Sept 2021 | - | $29.47 M(-0.3%) | $117.84 M(+2.2%) |
| June 2021 | - | $29.55 M(-6.7%) | $115.35 M(+4.7%) |
| Mar 2021 | - | $31.68 M(+16.7%) | $110.14 M(+5.2%) |
| Dec 2020 | $104.68 M(+6.0%) | $27.14 M(+0.6%) | $104.68 M(-0.0%) |
| Sept 2020 | - | $26.98 M(+10.8%) | $104.69 M(+2.9%) |
| June 2020 | - | $24.35 M(-7.1%) | $101.69 M(+1.8%) |
| Mar 2020 | - | $26.22 M(-3.4%) | $99.92 M(+1.2%) |
| Dec 2019 | $98.71 M(+21.2%) | $27.14 M(+13.2%) | $98.71 M(+3.5%) |
| Sept 2019 | - | $23.98 M(+6.2%) | $95.35 M(+5.8%) |
| June 2019 | - | $22.58 M(-9.7%) | $90.08 M(+2.6%) |
| Mar 2019 | - | $25.01 M(+5.2%) | $87.76 M(+7.8%) |
| Dec 2018 | $81.44 M(+55.5%) | $23.78 M(+27.0%) | $81.44 M(+16.3%) |
| Sept 2018 | - | $18.72 M(-7.6%) | $70.00 M(+10.5%) |
| June 2018 | - | $20.26 M(+8.4%) | $63.34 M(+7.2%) |
| Mar 2018 | - | $18.69 M(+51.5%) | $59.08 M(+12.8%) |
| Dec 2017 | $52.36 M(+18.3%) | $12.34 M(+2.3%) | $52.36 M(-0.8%) |
| Sept 2017 | - | $12.05 M(-24.6%) | $52.79 M(+3.5%) |
| June 2017 | - | $16.00 M(+33.6%) | $50.98 M(+10.8%) |
| Mar 2017 | - | $11.98 M(-6.1%) | $46.02 M(+3.9%) |
| Dec 2016 | $44.27 M(+2.3%) | $12.76 M(+24.5%) | $44.28 M(-1.1%) |
| Sept 2016 | - | $10.25 M(-7.1%) | $44.75 M(+1.6%) |
| June 2016 | - | $11.04 M(+7.9%) | $44.04 M(+2.0%) |
| Mar 2016 | - | $10.23 M(-22.7%) | $43.19 M(-0.2%) |
| Dec 2015 | $43.27 M(+5.7%) | $13.23 M(+38.7%) | $43.27 M(+2.3%) |
| Sept 2015 | - | $9.54 M(-6.3%) | $42.28 M(+1.0%) |
| June 2015 | - | $10.18 M(-1.2%) | $41.87 M(+1.4%) |
| Mar 2015 | - | $10.30 M(-15.9%) | $41.30 M(+0.9%) |
| Dec 2014 | $40.92 M(+1.0%) | $12.25 M(+34.2%) | $40.92 M(+6.3%) |
| Sept 2014 | - | $9.13 M(-5.1%) | $38.51 M(-3.8%) |
| June 2014 | - | $9.62 M(-3.1%) | $40.02 M(+1.0%) |
| Mar 2014 | - | $9.93 M(+1.0%) | $39.63 M(-2.2%) |
| Dec 2013 | $40.53 M(-2.6%) | $9.83 M(-7.6%) | $40.53 M(-2.5%) |
| Sept 2013 | - | $10.64 M(+15.4%) | $41.56 M(+1.4%) |
| June 2013 | - | $9.23 M(-14.8%) | $40.99 M(-2.5%) |
| Mar 2013 | - | $10.83 M(-0.3%) | $42.03 M(+1.0%) |
| Dec 2012 | $41.61 M(-11.0%) | $10.86 M(+7.9%) | $41.61 M(-1.5%) |
| Sept 2012 | - | $10.07 M(-1.9%) | $42.25 M(-5.1%) |
| June 2012 | - | $10.27 M(-1.4%) | $44.53 M(-2.0%) |
| Mar 2012 | - | $10.41 M(-9.4%) | $45.45 M(-2.8%) |
| Dec 2011 | $46.76 M(+14.1%) | $11.50 M(-6.9%) | $46.76 M(-0.2%) |
| Sept 2011 | - | $12.35 M(+10.4%) | $46.85 M(+4.9%) |
| June 2011 | - | $11.19 M(-4.6%) | $44.68 M(+2.2%) |
| Mar 2011 | - | $11.73 M(+1.2%) | $43.70 M(+6.6%) |
| Dec 2010 | $40.99 M(-0.0%) | $11.59 M(+13.8%) | $40.99 M(+1.5%) |
| Sept 2010 | - | $10.18 M(-0.3%) | $40.38 M(+0.7%) |
| June 2010 | - | $10.21 M(+13.2%) | $40.12 M(+2.9%) |
| Mar 2010 | - | $9.01 M(-17.9%) | $39.00 M(-4.9%) |
| Dec 2009 | $41.01 M | $10.98 M(+10.7%) | $41.01 M(-8.0%) |
| Sept 2009 | - | $9.92 M(+9.1%) | $44.57 M(-4.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2009 | - | $9.09 M(-17.5%) | $46.80 M(-7.9%) |
| Mar 2009 | - | $11.02 M(-24.2%) | $50.81 M(-1.3%) |
| Dec 2008 | $51.50 M(-10.1%) | $14.55 M(+19.7%) | $51.50 M(-0.8%) |
| Sept 2008 | - | $12.15 M(-7.2%) | $51.89 M(-0.5%) |
| June 2008 | - | $13.09 M(+11.8%) | $52.17 M(-0.2%) |
| Mar 2008 | - | $11.71 M(-21.6%) | $52.26 M(-8.8%) |
| Dec 2007 | $57.28 M(-30.4%) | $14.94 M(+20.3%) | $57.28 M(-10.2%) |
| Sept 2007 | - | $12.43 M(-5.7%) | $63.82 M(-1.5%) |
| June 2007 | - | $13.18 M(-21.3%) | $64.81 M(-16.6%) |
| Mar 2007 | - | $16.73 M(-22.1%) | $77.70 M(-4.5%) |
| Dec 2006 | $82.36 M(+87.8%) | $21.48 M(+60.0%) | $81.34 M(+10.6%) |
| Sept 2006 | - | $13.42 M(-48.5%) | $73.52 M(+3.5%) |
| June 2006 | - | $26.06 M(+27.9%) | $71.04 M(+28.9%) |
| Mar 2006 | - | $20.37 M(+49.2%) | $55.12 M(+25.7%) |
| Dec 2005 | $43.85 M(+41.6%) | $13.66 M(+24.8%) | $43.85 M(+12.8%) |
| Sept 2005 | - | $10.95 M(+8.0%) | $38.88 M(+10.1%) |
| June 2005 | - | $10.13 M(+11.3%) | $35.31 M(+15.2%) |
| Mar 2005 | - | $9.11 M(+4.9%) | $30.66 M(+8.0%) |
| Dec 2004 | $30.97 M(+40.7%) | $8.69 M(+17.7%) | $28.38 M(+8.3%) |
| Sept 2004 | - | $7.38 M(+34.7%) | $26.20 M(+9.1%) |
| June 2004 | - | $5.48 M(-19.8%) | $24.01 M(+1.4%) |
| Mar 2004 | - | $6.83 M(+4.8%) | $23.67 M(+7.5%) |
| Dec 2003 | $22.02 M(-15.4%) | $6.51 M(+25.5%) | $22.02 M(-8.3%) |
| Sept 2003 | - | $5.19 M(+1.1%) | $24.01 M(-5.4%) |
| June 2003 | - | $5.14 M(-0.8%) | $25.37 M(-1.7%) |
| Mar 2003 | - | $5.18 M(-39.1%) | $25.81 M(-0.8%) |
| Dec 2002 | $26.02 M(+37.9%) | $8.51 M(+29.9%) | $26.02 M(+17.4%) |
| Sept 2002 | - | $6.55 M(+17.5%) | $22.17 M(+3.7%) |
| June 2002 | - | $5.58 M(+3.6%) | $21.38 M(+5.7%) |
| Mar 2002 | - | $5.38 M(+15.4%) | $20.22 M(+7.2%) |
| Dec 2001 | $18.86 M(+35.4%) | $4.66 M(-19.1%) | $18.86 M(+2.3%) |
| Sept 2001 | - | $5.76 M(+30.4%) | $18.44 M(+17.1%) |
| June 2001 | - | $4.42 M(+10.0%) | $15.74 M(+9.2%) |
| Mar 2001 | - | $4.02 M(-5.1%) | $14.41 M(+3.5%) |
| Dec 2000 | $13.93 M(+77.0%) | $4.24 M(+38.2%) | $13.93 M(+14.5%) |
| Sept 2000 | - | $3.07 M(-0.9%) | $12.16 M(+7.7%) |
| June 2000 | - | $3.10 M(-12.4%) | $11.30 M(+11.8%) |
| Mar 2000 | - | $3.54 M(+43.2%) | $10.10 M(+29.0%) |
| Dec 1999 | $7.87 M(-6.2%) | $2.47 M(+12.2%) | $7.83 M(-1.5%) |
| Sept 1999 | - | $2.20 M(+15.8%) | $7.95 M(+5.3%) |
| June 1999 | - | $1.90 M(+50.3%) | $7.55 M(-1.6%) |
| Mar 1999 | - | $1.26 M(-51.1%) | $7.68 M(-7.9%) |
| Dec 1998 | $8.39 M(+32.5%) | $2.59 M(+43.7%) | $8.34 M(+6.4%) |
| Sept 1998 | - | $1.80 M(-11.1%) | $7.83 M(+6.2%) |
| June 1998 | - | $2.02 M(+5.2%) | $7.38 M(+7.4%) |
| Mar 1998 | - | $1.93 M(-7.6%) | $6.87 M(+8.6%) |
| Dec 1997 | $6.33 M(+58.2%) | $2.08 M(+54.9%) | $6.33 M(+6.5%) |
| Sept 1997 | - | $1.34 M(-11.3%) | $5.94 M(+10.1%) |
| June 1997 | - | $1.52 M(+9.8%) | $5.40 M(+12.9%) |
| Mar 1997 | - | $1.38 M(-18.7%) | $4.78 M(+16.6%) |
| Dec 1996 | $4.00 M(+25.0%) | $1.70 M(+112.5%) | $4.10 M(+28.1%) |
| Sept 1996 | - | $800.00 K(-11.1%) | $3.20 M(+3.2%) |
| June 1996 | - | $900.00 K(+28.6%) | $3.10 M(+3.3%) |
| Mar 1996 | - | $700.00 K(-12.5%) | $3.00 M(-9.1%) |
| Dec 1995 | $3.20 M(-56.8%) | $800.00 K(+14.3%) | $3.30 M(-61.2%) |
| Sept 1995 | - | $700.00 K(-12.5%) | $8.50 M(+1.2%) |
| June 1995 | - | $800.00 K(-20.0%) | $8.40 M(+5.0%) |
| Mar 1995 | - | $1.00 M(-83.3%) | $8.00 M(+8.1%) |
| Dec 1994 | $7.40 M | $6.00 M(+900.0%) | $7.40 M(+428.6%) |
| Sept 1994 | - | $600.00 K(+50.0%) | $1.40 M(+75.0%) |
| June 1994 | - | $400.00 K(0.0%) | $800.00 K(+100.0%) |
| Mar 1994 | - | $400.00 K | $400.00 K |
FAQ
- What is Nektar Therapeutics annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Nektar Therapeutics?
- What is Nektar Therapeutics annual SG&A year-on-year change?
- What is Nektar Therapeutics quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Nektar Therapeutics?
- What is Nektar Therapeutics quarterly SG&A year-on-year change?
- What is Nektar Therapeutics TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Nektar Therapeutics?
- What is Nektar Therapeutics TTM SG&A year-on-year change?
What is Nektar Therapeutics annual selling, general & administrative expenses?
The current annual SG&A of NKTR is $77.42 M
What is the all time high annual SG&A for Nektar Therapeutics?
Nektar Therapeutics all-time high annual selling, general & administrative expenses is $122.84 M
What is Nektar Therapeutics annual SG&A year-on-year change?
Over the past year, NKTR annual selling, general & administrative expenses has changed by -$14.92 M (-16.15%)
What is Nektar Therapeutics quarterly selling, general & administrative expenses?
The current quarterly SG&A of NKTR is $18.96 M
What is the all time high quarterly SG&A for Nektar Therapeutics?
Nektar Therapeutics all-time high quarterly selling, general & administrative expenses is $32.14 M
What is Nektar Therapeutics quarterly SG&A year-on-year change?
Over the past year, NKTR quarterly selling, general & administrative expenses has changed by -$2.19 M (-10.36%)
What is Nektar Therapeutics TTM selling, general & administrative expenses?
The current TTM SG&A of NKTR is -$14.16 B
What is the all time high TTM SG&A for Nektar Therapeutics?
Nektar Therapeutics all-time high TTM selling, general & administrative expenses is $122.84 M
What is Nektar Therapeutics TTM SG&A year-on-year change?
Over the past year, NKTR TTM selling, general & administrative expenses has changed by -$14.24 B (-17362.16%)